Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
03/2009
03/19/2009US20090075879 Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus
03/19/2009US20090075873 Gastrin compositions and formulations, and methods of use and preparation
03/19/2009US20090075839 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigents and uses thereof
03/19/2009US20090075373 Neural progenitor cells derived from embryonic stem cells
03/19/2009US20090075327 Methods for improving secondary metabolite production in fungi
03/19/2009US20090075303 Allo and Auto-Reactive T-Cell Epitopes
03/19/2009US20090074890 Substituted Triazoles as Sodium Channel Blockers
03/19/2009US20090074870 Alteration of cell membrane for new functions
03/19/2009US20090074859 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
03/19/2009US20090074858 Sustained-release formulation
03/19/2009US20090074851 Cpg-packaged liposomes
03/19/2009US20090074818 Composition Comprising Parasite Eggs And Methods For Isolation And Storage Of Parasite Eggs
03/19/2009US20090074813 Compositions And Methods Using Variant Tat Proteins
03/19/2009US20090074802 Immunomodulating oligopeptides
03/19/2009US20090074797 useful in the management of various cancers which express 20P2H8, particularly including cancers of the bladder, prostate, colon and pancreas
03/19/2009US20090074794 for use in the treatment of crohn's and ulcerative colitis; administering a composition comprising an effective amount of at least one isolated mammalian anti-tumor necrosis factor (TNF) antibody comprising at least one variable region comprising SEQ ID NO:7 and 8
03/19/2009US20090074793 High Affinity Human Antibodies to Human IL-4 Receptor
03/19/2009US20090074792 Compositions containing full-length L1R nucleic acid and endoplasmic reticulum-targeting sequence, and methods of use
03/19/2009US20090074771 FcGammaRIIB Specific Antibodies and Methods of Use Thereof
03/19/2009US20090074760 Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant
03/19/2009US20090074747 Methods and Compositions for Treating Allergic Diseases
03/19/2009US20090074720 Methods for decreasing immune response and treating immune conditions
03/19/2009CA2731204A1 Use of a peptide as a therapeutic agent
03/19/2009CA2704726A1 Use of a defensin peptide as a therapeutic agent
03/19/2009CA2699222A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699215A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009CA2699167A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699026A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699020A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699012A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699010A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699008A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699006A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698992A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698985A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698984A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698981A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698980A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698978A1 Use of human neuropeptide af as a therapeutic agent
03/19/2009CA2698977A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
03/19/2009CA2698976A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698974A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698971A1 Use of urodilatin as a therapeutic agent
03/19/2009CA2698966A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009CA2698963A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698912A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698855A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698852A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698833A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698831A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698828A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698824A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
03/19/2009CA2698822A1 Minigastrin as a therapeutic agent
03/19/2009CA2698821A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698786A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698783A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698778A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698770A1 Use of secretin and optionally urodilatin as a therapeutic agents
03/19/2009CA2698759A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698754A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698748A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698745A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698693A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698691A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698682A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698666A1 Use of a peptide as a therapeutic agent
03/18/2009EP2036926A2 Single-chain, multiple antigen forming molecule, its manufacture and use
03/18/2009EP2036891A2 Isoquinoline inhibitors of P38
03/18/2009EP2036573A1 HLA binding peptides and their uses
03/18/2009EP2036569A2 Method for Treating Secondary Immunodeficiency
03/18/2009EP2036560A1 (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy
03/18/2009EP2035413A2 Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors
03/18/2009EP1539927B1 Probiotic bacterium: lactobacillus fermentum
03/18/2009EP1448993B1 Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules
03/18/2009EP1389096B1 Delivery of opioids through an inhalation route
03/18/2009EP1368044B1 Immunomodulator for the management of human immunodeficiency virus (hiv) disease/infection
03/18/2009EP0741783B1 Vertebrate embryonic pattern-inducing hedgehog-like proteins
03/18/2009CN101389626A Fused ring heterocycle kinase modulators
03/18/2009CN101389612A 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
03/18/2009CN101389611A Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
03/18/2009CN101389321A Use of resveratrol and derivatives thereof for promoting the wellness state in mammals
03/18/2009CN101387646A Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
03/18/2009CN101386875A Synthesis of conjugate linoleate sugar esters derivates based on enzymatic method
03/18/2009CN101386848A MiRNA with cell corpuscule as vector and preparation research approach thereof and application
03/18/2009CN101386643A Expression of vibrio alginolyticus outer membrane protein VA0760 and application thereof as vaccine component
03/18/2009CN101386642A Expression of vibrio alginolyticus outer membrane protein VA0760 and application thereof as vaccine component
03/18/2009CN101386580A Aminopropancdiols derivates, preparation method thereof and medicament composition and use thereof
03/18/2009CN101385830A Ultra-high biomass full-energy high biological activity polymer brain activity traditional Chinese medicine preparation
03/18/2009CN101385789A Medicine for increasing leucocyte and preparation method thereof
03/18/2009CN101385782A Preparation method of buckwheat germ rutin capsule
03/18/2009CN101385776A Anti influenza use of main chemical component and active component in scabriculous herbamoslae
03/18/2009CN101385750A Preparation method of effective ingredient of isatis root
03/18/2009CN101385742A CD4+CD25+regulatory T cells from human blood
03/18/2009CN100469793C Anti-osteopontin antibody and use thereof
03/18/2009CN100469789C Variants of allergenic proteins of the Group2 of dermatophagoides
03/18/2009CN100469784C Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
03/18/2009CN100469783C Oligose ,sulfating product and oligose cluster and its uses
03/18/2009CN100469778C Novel fused imidazole derivative
03/18/2009CN100469767C Bipiperidinyl-derivatives and their use as chemokine receptor inhibitors
03/18/2009CN100469393C Sphingoid polyalkylamine conjugates for vaccination
1 ... 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 ... 1172